PUT - SPRINTER OPEN END - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 07:41:45 2024-06-26 EDT | ||
| 2.72 EUR | 0.00% |
|
| Current month | -2.16% | ||
| 3 months | +51.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 2.72 | 0.00% |
| 24-06-25 | 2.72 | +0.74% |
| 24-06-24 | 2.7 | -3.23% |
| 24-06-21 | 2.79 | -1.41% |
| 24-06-20 | 2.83 | +1.07% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 07:41 am
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU3MS6 |
| ISIN | DE000VU3MS67 |
| Date issued | 2023-02-15 |
| Strike | 71.17 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.86 € |
|---|---|
| Lowest since issue | 0.115 € |
| Spread | 0.02 € |
| Spread % | 0.73% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.19
USD
Average target price
53.19
USD
Spread / Average Target
+26.08%
- Stock Market
- Certificates
- Certificat
